Lead Program in Hemophilia B Be Biopharma's recognition as the Lead Program in Hemophilia B, with an anticipated IND filing in mid-2024, presents a prime opportunity for partnership and collaboration in the rare disease field.
Key Personnel Additions The recent hire of John Mayfield as Chief Business Officer signifies strategic growth and potential new business initiatives, offering a chance for synergistic relationships and networking opportunities.
Series B Funding Success Securing $130 million in Series B funding indicates financial stability and growth prospects, making Be Biopharma an attractive target for investment opportunities or service provision partnerships.
Investment in Aurion Biotech Be Biopharma's investment in Aurion Biotech demonstrates a strategic focus on innovative technologies and therapeutics, opening doors for collaboration or joint ventures in advancing cutting-edge treatments.
Board of Directors Expansion Adding Dr. Gillis to the Board of Directors enhances Be Biopharma's leadership strength and strategic decision-making capabilities, which could lead to potential strategic alliances or advisory opportunities.
93K
$1B
38K$1B
87K$1B
103K$1B
102K$1B
73K$1B
54K$1B
8.2K$1B
78K$1B
92K$1B
36K$1BBe Biopharma uses 8 technology products and services including Cloudflare CDN, Google Cloud, Popper, and more. Explore Be Biopharma's tech stack below.
| Be Biopharma Email Formats | Percentage |
| FLast@be.bio | 86% |
| First@be.bio | 7% |
| First.Last@be.bio | 6% |
| FL@be.bio | 1% |
Biotechnology ResearchMassachusetts, United States51-200 Employees
Be Bio is pioneering Engineered B Cell Medicines (BCMs) to dramatically improve the lives of patients who are living with Hemophilia B and other genetic diseases, cancer, and other serious conditions. With eyes locked on the patient, our team of purpose-driven scientists, technologists, manufacturing experts and business builders collaborate to create a bold new class of cell therapies.
Company Overview
Media & News
Funding & FinancialsBe Biopharma has raised a total of $130M of funding over 2 rounds. Their latest funding round was raised on Apr 14, 2022 in the amount of $130M.
Be Biopharma's revenue is in the range of $10M$50M
Funding & FinancialsBe Biopharma has raised a total of $130M of funding over 2 rounds. Their latest funding round was raised on Apr 14, 2022 in the amount of $130M.
Be Biopharma's revenue is in the range of $10M$50M
1-888-653-2347 
support@leadiq.com